Home

L. Clinical Treatment and Outcome Trials Involving Adult Community-Acquired Infections, Including Obstetrical-Gynecological and Sexually Transmitted Infections

 

Meet-the-Experts

 

Difficult to Manage Cutaneous Infections in Adults and Children

Skin and soft tissue infections are common problems that are increasingly challenging due to drug resistant pathogens and immunocompromised hosts. The diagnosis and management of common and uncommon skin and soft tissue infections have evolved to meet these challenges. This Meet-the-Expert session will be of particular interest for those involved in the care or investigation of cutaneous infections of adults or children.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

• Discriminate important infections of skin and soft tissue;
• Describe the approach to diagnosing and managing challenging skin and soft tissue infections; and 
• Improve their care of patients with cutaneous infections. 

Experts:
John W. Baddley, MD, MSPH; Univ. of Alabama, Birmingham, AL.
Clarence Creech, MD, MPH; Vanderbilt Univ. Sch. of Med., Nashville, TN.

 

Challenging Infections in Older Adults

Infections are a major cause of morbidity and mortality in older adults. The prevention, diagnosis and management of infections are challenging in older adults. Healthcare-associated infections are particularly problematic in older adults, particularly in assisted living and skilled nursing facilities. Vaccines are underutilized in older adults. This Meet-the-Experts will be of interest to those with an interest in infectious diseases that affect older adults.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

• Identify important infectious diseases in older adults;
• Describe the impact of infections on older adults; and 
• Improve their care of older adults with infections. 

Experts:
Ebbing Lautenbach, MD, MPH; Univ. of Pennsylvania Sch. of Med., Philadelphia, PA.
Preeti N. Malani, MD, MSJ; Univ. of Michigan, Ann Arbor, MI.

 

Symposia

 

50 Years of Fluoroquinolones: Past, Present and Future

Developed in cooperation with the International Society of Chemotherapy (ISC).

Attendees will gain a greater understanding regarding the fluoroquinolone drug class. This will include the history of drug development, the clinical use of these important agents (new and old), the emergence of resistance and their adverse effects. In addition, emerging new agents in this class will be discussed.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss the fluoroquinolone drug class, including the emergence of resistance;
• Describe how to effectively use fluoroquinolones for clinical care, including both efficacy and adverse reactions; and 
• Identify new fluoroquinolone agents that are under development. 

Conveners:
David C. Hooper, MD; Harvard Med. Sch., Boston, MA.
Teresita Mazzei, MD; Univ. of Florence, Florence, Italy.

Presentations:
New Novel Uses of Fluoroquinolones Including Polyoma Virus, Leprosy, MTB
Ethan Rubinstein, MD; Univ. of Manitoba, Winnipeg, Canada.

Use and Abuse: Why, How and So What?
Ian Gould, MD; Aberdeen Royal Infirmary, Aberdeen, United Kingdom.

New Quinolones: What’s on the Horizon?
David C. Hooper, MD; Harvard Med. Sch., Boston, MA.

 

An Update on Novel & Important Tickborne Diseases

This session will provide an update on emerging and important tickborne diseases. It will touch on newly described human pathogens, such as novel Ehrlichia and Borrelia species. There will be an overview of the diverse rickettsial bacteria that are transmitted by ticks and an update on transfusion-associated babesiosis. The emergence of deer tick virus-associated encephalitis will be discussed.

Upon completion of this Symposium Session, the participant should be able to:

• Identify major tickborne pathogens;
• Define diagnostic and therapeutic aspects of tickborne infections; 
• Analyze features of emerging deer tick virus encephalitis; and 
• Improve knowledge about new tick-associated infections. 

Conveners:
Didier Raoult, MD, PhD; WHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille, France.
Bobbi S. Pritt, MD; Mayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN.

Presentations:
Emergence of a New Pathogenic Ehrlichia Species, Wisconsin and Minnesota
Bobbi S. Pritt, MD; Mayo Clinic and Mayo Clinic Coll. of Med., Rochester, MN.

Human Infections Caused by Borrelia miyamotoi
Peter J. Krause, MD; Yale Sch. of Publ. Hlth. and Yale Sch. of Med., New Haven, CT.

Diverse Rickettsiae Across the Globe
Didier Raoult, MD, PhD; WHO Collaborative Ctr. for Rickettsial Reference and Res., Marseille, France.

Transfusion-Associated Babesiosis
Barbara Herwaldt, MD; MPH, CDC, Atlanta, GA.

Emergence of Deer Tick Virus as a Human Pathogen
Gary P. Wormser, MD; New York Med. Coll., Valhalla, NY.

 

An Update on Streptococcal Pharyngitis and Rheumatic Fever

An update on the mechanisms underlying streptococcal pharyngitis pathogenesis , epidemiology, diagnosis and management, coupled with an update on one of the immunological consequences of streptococcal pharyngitis: rheumatic fever.

Upon completion of this Symposium Session, the participant should be able to:

• Identify key pathogenetic factors that enable S. pyogenes to cause pharyngeal infection;
• Diagnose and manage Strep pharyngitis in the modern era; and 
• Discuss the epidemiology of Strep pharyngitis and rheumatic fever. 

Conveners:
Shiranee Sriskandan, MD, PhD; Imperial Coll., London, United Kingdom.
Andrew Steer, MD, PhD; Univ. of Melbourne and Royal Children’s Hosp., Melbourne, Australia.

Presentations:
Overview of GAS Pathogenesis in Pharyngitis
Michael Wessels, MD, PhD; Children's Hosp. Boston, Harvard Med. Sch., Boston, MA.

Update on Diagnosis and Management of Streptococcal Pharyngitis
Stanford T. Shulman, MD; Northwestern Univ. Feinberg Sch. of Med., Chicago, IL.

Rheumatic Fever 2012 and Beyond
Andrew Steer, MD, PhD; Univ. of Melbourne and Royal Children’s Hosp., Melbourne, Australia.

 

Dangerous Pets and Other Animals

Attendees will gain a greater understanding about the role of animals in the transmission of disease, as well as the management of animal bites. In addition, attendees will have an improved understanding about new methods of diagnosing hard to detect zoonotic infections.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss how to diagnose zoonotic infections;
• Effectively treat infections related to animal bites; and 
• Identify new concepts regarding the epidemiology of newly recognized zoonotic infections. 

Convener:
M. Lindsay Grayson, MD; Univ. of Melbourne, Austin Hlth., Melbourne, Australia.

Presentations:
The Role of Bats in the Transmission of Dangerous Zoonotic Viruses
Lin-Fa Wang, PhD; Australian Animal Hlth. Lab., Geelong, Australia.

Microbe Hunting: New Approaches to Diagnosing Undiscovered Pathogens
TBA

MRSA and Animals
Tara C. Smith, PhD; Univ. of Iowa, Iowa City, IA.

Once Bitten, Twice Shy: Animal Bites in Infectious Diseases
David F. Looke, MBBS, FRACP, FRCPA; Princess Alexandra Hosp., Univ. of Queensland, Brisbane, Australia.

 

Emerging and Current Challenges

Session will provide an overview of emerging infections seen in injecting drug users over the last three years, both those occurring as part of small epidemics, as well as those that represent an on-going risk to the injecting drug user community.

Upon completion of this Symposium Session, the participant should be able to:

• Identify new threats to injecting drug users and how such infections may present; and
• Identify such infections and be aware of treatment options available. 

Conveners:
Shiranee Sriskandan, MD, PhD; Imperial Coll., London, United Kingdom.
Donald Levine, MD; Wayne State Univ., Detroit, MI.

Presentations:
Wound Botulism in Injecting Drug Users
Duc J. Vugia, MD, MPH; California Dept. of Pub. Hlth., Richmond, CA.

An Outbreak of Anthrax in Injecting Drug Users
Tim J. Brooks, MA, MSc, FRCPath, FRSPH; Hlth. Protection Agency, Porton Down, United Kingdom.

Update on Endocarditis in Drug Users
Donald Levine, MD; Wayne State Univ., Detroit, MI.

 

New Issues in the Management of MDR/XDR TB

Session will provide an up to date overview of difficult-to-treat tuberculosis, focusing on those infections where resistance to two or more than two drugs poses additional challenges. The emphasis will be on clinical management of such cases, including new approaches to diagnosis, drug treatment, as well as surgical treatment of suitable cases. WHO guidance on use of established second line drugs will be reviewed, as will the potential of newer drugs to provide alternative options for management.

Upon completion of this Symposium Session, the participant should be able to:

• Identify new diagnostic approaches for resistance testing in Mycobacterium tuberculosis;
• Identify internationally-accepted management standards for treating cases of MDR and XDR M. tuberculosis; and 
• Identify options for alternative medical and surgical options in difficult to treat cases. 

Conveners:
William Bishai, MD, PhD; Kwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV, Johns Hopkins Ctr. for Tuberculosis Res., Durban, South Africa.
Shiranee Sriskandan, MD, PhD; Imperial Coll., London, United Kingdom.

Presentations:
MDR TB: View from the Frontline 
William Bishai, MD, PhD; Kwa-Zulu-Natal Res. Inst. for Tuberculosis and HIV, Johns Hopkins Ctr. for Tuberculosis Res., Durban, South Africa.

New Diagnostics for MDR TB
Mark Perkins, MD; Fndn. for Innovative Diagnostics, Geneva, Switzerland.

MDR TB: Status, Treatment and Control Measures
Mario C. Raviglione, MD; World Hlth. Organization, Geneva, Switzerland.

Surgery for MDR and Difficult to Treat TB
John D. Mitchell, MD; Univ. of Colorado Sch. of Med., Natl. Jewish Health, Denver, CO.

New Drugs in the Clinical Pipeline for TB
Mel Spigelman, MD; Global Alliance for TB Drug Dev., New York, NY.

 

New Issues in the Management of Multidrug-Resistant (MDR) Endocarditis

Developed in Cooperation with the Infectious Diseases Society of America (IDSA)

Attendees will gain a greater understanding about the diagnosis and management of endocarditis and other serious intravascular infections due to multidrug-resistant pathogens.

Upon completion of this Symposium Session, the participant should be able to:

• Describe how to diagnose multidrug-resistant intravascular infections;
• Assess how to effectively treat multi-drug resistant endocarditis and intravascular infections; and 
• Discuss the current development pathway for new agents and other approaches for endocarditis. 

Conveners:
M. Lindsay Grayson, MD; Univ. of Melbourne, Austin Hlth., Melbourne, Australia.
Henry F. Chambers, MD; San Francisco Gen. Hosp., San Francisco, CA.

Presentations:
MDR Staphylococcus aureus Endocarditis (MRSA, hVISA)
Henry F. Chambers, MD; San Francisco Gen. Hosp., San Francisco, CA.

Endocarditis Due to VRE and Other Resistant Enterococci
Robert C. Moellering, Jr., MD; Harvard Med. Sch., Boston, MA.

MDR Gram-Negative Endocarditis
David L. Paterson, MD, PhD; Univ. of Queensland Ctr. for Clinicial Res., Brisbane, Australia.

Q Fever Endocarditis and Intravascular Infections
Bart-Jan Kullberg, MD, PhD, FRCP; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands. 

 

New Insights in Diabetic Foot Infections and Osteomyelitis

Diabetic foot infections are an increasing problem. Multidrug resistant organisms render these infections more difficult to treat. Osteomyelitis in the infected foot is often difficult to diagnose and manage. The use of antimicrobials can be optimized by understanding their clinical pharmacology.

Upon completion of this Symposium Session, the participant should be able to:

• Define the impact of multidrug resistant pathogens to the management of diabetic foot infections;
• Analyze options for diagnosing bone infections in the diabetic foot; 
• Determine the optimal dosing for antimicrobials used in the treatment of infections in diabetic feet; and 
• Manage diabetic foot infections in a more rational way. 

Conveners:
Anthony R. Berendt, FRCP; Nuffield Orthopaedic Ctr., Headington, United Kingdom.
Adolf W. Karchmer, MD; Beth Israel Deaconess Med. Ctr., Boston, MA.

Presentations:
Do Clinical Guideline Help Us Manage DFIs Caused by Multidrug-Resistant Organisms?
Anthony R. Berendt, FRCP; Oxford Univ. Hosp. NHS Trust, Oxford, United Kingdom.

Drug Dosing for Complicated DFIs: Maximizing PK/PD
David P. Nicolau, PharmD; Hartford Hosp., Hartford, CT.

New Diagnostic Approaches to Diabetic Foot Osteomyelitis
Benjamin A. Lipsky, MD; VA Puget Sound Hlth. Care System, Seattle, WA, Seattle, WA.

Medical Management of Osteomyelitis: How to Prevent Amputations
Adolf W. Karchmer, MD; Beth Israel Deaconess Med. Ctr., Boston, MA.

 

Potluck: The Latest on Foodborne Infections

Foodborne infections are an increasingly important challenge. Modern food distribution and globalization have impacted the epidemiology of foodborne infections. The diagnosis and management of such infections are evolving. Though common foodborne infections may be self-limited, complications such as hemolytic uremic syndrome can be fatal.

Upon completion of this Symposium Session, the participant should be able to:

• Define possible foodborne infections in patients presenting with gastroenteritis; • 
• Differentiate among the common etiologies of food-related infectious diseases; and • 
• Summarize new information about the diagnosis and management of foodborne infectious diseases.

Conveners:
Hoonmo L. Koo, MD; Baylor Coll. of Med., Houston, TX.
Ansgar W. Lohse, MD; Univ. Med. Ctr., Hamburg, Germany.

Presentations:
Listeriosis: From Milk to Melons
Benjamin Silk, PhD; CDC, Atlanta, GA.

Foodborne Norovirus Outbreak
Hoonmo L. Koo, MD; Baylor Coll. of Med., Houston, TX.

Salmonellosis: Recalls and Contaminated Products
Casey Barton Behravesh, DVM, DrPH; CDC, Atlanta, GA.

Parasitic Infections in the Water Supply
Julia Gargano, PhD; CDC, NCEZID, Atlanta, GA.

E. coli: Pathogenesis and Treatment of EHEC/HUS
Ansgar W. Lohse, MD; Univ. Med. Ctr., Hamburg, Germany.

 

What Every Clinician Should Know About Emerging New Antimicrobials

Attendees will gain a greater understanding about new emerging antimicrobial agents and how they can, or are likely to be, used in clinical practice. In vivo and in vitro efficacy, toxicity, pharmacokinetics/pharmacodynamics and drug interactions will be discussed.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss the new emerging antimicrobial agents;
• Recognize when these new agents may be of value in clinical practice; 
• Assess how to safely use these new agents; and 
• Identify the current development pathway for these new agents. 

Conveners:
M. Lindsay Grayson, MD; Univ. of Melbourne, Austin Hlth., Melbourne, Australia.
George M. Eliopoulos, MD; Beth Israel Deaconess Med. Ctr., Boston, MA.

Presentations:
Fidaxomicin and Other Macrocyclic Antibiotics
Kathleen Mullane, DO, PharmD; Univ. of Chicago, Chicago, IL.

New Oxazolidinones, Including Tedizolid (Torezolid, TR-700)
George M. Eliopoulos, MD; Beth Israel Deaconess Med. Ctr., Boston, MA.

Ceftaroline: An Update
Helen W. Boucher, MD, FACP; Tufts Med. Ctr., Boston, MA.

New Beta-Lactam/Beta-Lactamase Combinations: Cephalosporins and Avibactam or Tazobactam
David M. Livermore, PhD; Univ. of East Anglia, Norwich, United Kingdom.

Plazomicin (ACHN-490) and Other New Aminoglycosides
Karen Bush, PhD; Indiana Univ., Bloomington, IN.

Boron-Based Antimicrobials
David J. Payne, PhD; GlaxoSmithKline, Collegeville, PA.

 

What's New with Pneumococcus?

Streptococcus pneumoniae is a major cause of respiratory tract infections in children and adults. The management of such infections is challenging due to increasing antimicrobial resistance among S. pneumoniae strains. Vaccination is important for preventing invasive pneumococcal infections but their use might impact the patterns of disease in immunized and nonvaccinated patients. This session will be relevant to those interested in respiratory tract infections, streptococcal infections, antimicrobial resistance and vaccine preventable diseases.

Upon completion of this Symposium Session, the participant should be able to:

• Describe the impact of antimicrobial resistance to the management of S. pneumoniae infections;
• Improve their clinical care of patients at risk for and infected with pneumococcus; 
• Critically analyze recent data regarding the global spread of antimicrobial resistance in pneumococcus; and 
• Define the impact of vaccination on global patterns of clinical disease. 

Conveners:
Keith P. Klugman, MD, PhD; Rollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA.
Patrick G. P. Charles, MBBS, PhD; Austin Hlth., Heidelberg VIC, Australia.

Presentations:
What is the Clinical Impact of Penicillin Non-Susceptibility on Treatment Outcomes for Meningitis and Invasive Pneumococcal Disease?
Keith P. Klugman, MD, PhD; Rollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA.

New Mechanisms of Resistance and Their Clinical Impact
Alexander Tomasz, PhD; The Rockefeller Univ., New York, NY.

Does Penicillin Non-Susceptibility Really Matter When it Comes to Treating Pneumonia?
Patrick G. P. Charles, MBBS, PhD; Austin Hlth., Heidelberg VIC, Australia.

The Clinical Impact of Emerging Macrolide and Quinolone Resistance in North America
Thomas J. Marrie, MD; Dalhousie Univ., Halifax, Canada.

How has the New Polyvalent Pneumococcal Vaccine Altered Patterns of Clinical Disease?
Peter R. Paradiso, PhD; Pfizer Vaccines, Collegville, PA.

 

An Update on Perinatal Infections

Developed in cooperation with the Infectious Diseases Society of Obstetrics & Gynecology (IDSOG)

This symposium will cover new information about serious infections that complicate pregnancy. Infections during pregnancy are an important problem that threaten maternal and child health worldwide. Viral, bacterial, and parasitic infections can cause preterm birth, stillbirth, congenital infections of the fetus, and neonatal sepsis. This session will review key aspects of important infections that complicate pregnancy including diagnosis, prognosis, and therapeutics.

Upon completion of this Symposium Session, the participant should be able to:

• Define important infections that complicate pregnancy;
• Determine which antimicrobials are safe for use in pregnancy; and 
• Improve the care of pregnant women with infection or at risk for infection. 

Conveners:
Catherine Nelson-Piercy, FRCP; St. Thomas' Hosp., London, United Kingdom.
Michael G. Gravett, MD; Univ. of Washington Sch. of Med., Seattle, WA.

Presentations:
Safe Use of Antimicrobials in Pregnancy
Catherine Nelson-Piercy, FRCP; St. Thomas' Hosp., London, United Kingdom.

Influenza During Pregnancy
Richard Beigi, MD, MSc; Magee-Womens Hosp., Univ. of Pittsburgh Med. Ctr., Pittsburgh, PA.

Beyone TORCH: The New Paradigm for Pesky Perinatal Infections
Michael G. Gravett, MD; Univ. of Washington Sch. of Med., Seattle, WA.

Malaria and Other Parasitic Infections During Pregnancy
R. Philips Heine, MD; Duke Univ. Med. Ctr., Durham, NC.

 

An Update on the Treatment and Prevention of UTIs

This session deals with the treatment and prevention of UTIs. It will cover the use of natural products to prevent UTIs. Areas of discussion include the impact of MDR pathogens and the problem of asymptomatic bacteriuria in older adults.

Upon completion of this Symposium Session, the participant should be able to:

• Describe the role of cranberries and other natural products in UTI prevention;
• Improve their care of patients with UTIs caused by multidrug resistant pathogens; 
• Analyze the state of knowledge regarding asymptomatic bacteriuria; and 
• Improve prevention of catheter related UTIs. 

Conveners:
Lindsay E. Nicolle, MD; Univ. of Manitoba, Winnipeg, Canada.
Suzanne E. Geerlings, MD; Univ. Med. Ctr. Utrecht, Utrecht, Netherlands.

Presentations:
Do Cranberries or Other Natural Products Prevent UTIs?
Suzanne E. Geerlings, MD; Univ. Med. Ctr. Utrecht, Utrecht, Netherlands.

Empiric UTI Therapy in the Era of the ESBLs
Barbara K. Hasse, MD; Univ. Hosp. Zurich, Zurich, Switzerland.

Developments in Asymptomatic Bacteriuria and UTI in Older Populations
Lindsay E. Nicolle, MD; Univ. of Manitoba, Winnipeg, Canada.

Effective Strategies to Prevent Catheter-Associated UTIs
Barbara Trautner, MD, PhD; Baylor Coll. of Med., Houston, TX.